Visterra, Previously Parasol, Expands with $6M
Visterra, a Cambridge, MA-based developer of therapies and diagnostics for flu and other viruses, has raised a $6 million round of venture funding from Flagship Ventures, Lux Capital, and Polaris Venture Partners. The news was reported earlier by PE Hub and Mass High Tech. Visterra, formerly called Parasol Therapeutics, was spun out of the MIT lab of bioengineer Ram Sasisekharan and incubated at Polaris, as Ryan reported in April 2009. The company previously raised $3.25 million in seed funding. The new money is being used in part to help Visterra expand to Singapore, where it plans to extend its R&D capabilities.